A Prospective, Multicenter, Single-Arm, Open-Label Phase 2 Study of Chidamide Maintenance in Patients With Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma Who Achieve Complete Response After Induction Therapy But Remain ctDNA MRD-Positive
Latest Information Update: 07 Apr 2026
At a glance
- Drugs Tucidinostat (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms DEL-MRD-CHID
Most Recent Events
- 07 Apr 2026 New trial record